Tocilizumab : A new opportunity in the possible therapeutic arsenal against COVID-19
| Errataetall: |
CommentOn: Travel Med Infect Dis. 2020 May - Jun;35:101647. - PMID 32247927 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Travel medicine and infectious disease - 37(2020) vom: 18. Sept., Seite 101678 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ortiz-Martínez, Yeimer [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3QKI37EEHE |
|---|
| Anmerkungen: |
Date Completed 26.10.2020 Date Revised 28.03.2024 published: Print-Electronic CommentOn: Travel Med Infect Dis. 2020 May - Jun;35:101647. - PMID 32247927 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tmaid.2020.101678 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309094747 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309094747 | ||
| 003 | DE-627 | ||
| 005 | 20240328234455.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tmaid.2020.101678 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1352.xml |
| 035 | |a (DE-627)NLM309094747 | ||
| 035 | |a (NLM)32325121 | ||
| 035 | |a (PII)S1477-8939(20)30146-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ortiz-Martínez, Yeimer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tocilizumab |b A new opportunity in the possible therapeutic arsenal against COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.10.2020 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Travel Med Infect Dis. 2020 May - Jun;35:101647. - PMID 32247927 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a IL-6 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Travel medicine and infectious disease |d 2003 |g 37(2020) vom: 18. Sept., Seite 101678 |w (DE-627)NLM16457655X |x 1873-0442 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g day:18 |g month:09 |g pages:101678 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tmaid.2020.101678 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |b 18 |c 09 |h 101678 | ||